EQS-Adhoc: Achiko AG: Achiko Announces Completion of Financing Round and Updates to the Senior Management Team
Achiko Announces Completion of Financing Round and Updates to the Senior Management Team
Zurich, 29 July 2020 - Achiko AG (ACHI:SWX), has successfully completed the previously advised increase of its share capital and announces updates to the senior management team.
The Company has finalised a capital increase of USD 2 million subscribed by PT Media Nusantara Citra Tbk ("MNC") at USD 1.00 per share, coupled with a convertible note placed to Negma Group Ltd ("Negma"). for an additional CHF 2 million, and additional placements for cash and cash equivalents for a further 4,180,513 shares. The Negma convertible note may correspond up to 12,155,387 shares, depending on share price development and drawdowns. Additionally, the Company has issued shares of up to 5,000,000 shares to PT Indosterling Omni Kapita for advisory and market development services in Asia, specifically Indonesia. These transactions will bring the total number of issued shares to 100,812,655 plus any shares converted through the Negma convertible note.
Citing the changes to the Company's strategic direction in light of the Covid-19 pandemic, Steven Goh, a current member of the board of Achiko, was appointed as new CEO of Achiko. His existing compensation package remains unchanged. Kenneth Ting, the former CEO is retiring to pursue other opportunities.
Following the successful redomicile of Achiko to Switzerland and the formation of Achiko AG, the Company is pleased to announce the appointment of Swiss-based Rüdiger Petrikowski as CFO ad interim. In addition to his base salary, Rüdiger is entitled to up to 240,000 equity share options at a strike price of CHF 0.25 subject to meeting agreed performance objectives.
Rüdiger is an experienced CFO, M&A and Business Development professional with over 20 years of experience in the telecommunication, media, technology, payment and collection industries. He formerly served as CFO at Crypto Valley Venture Capital (CV VC), and prior to that held roles with PubliGroupe Ltd. and Swisscom.
To further the development of Achiko's business in Switzerland and Europe, especially in light of the recent success in Indonesia with the Teman Sehat ("Health Buddy") ecosystem and the plans to launch a new Covid-19 test kit, current board member Christophe Laurent is also joining the Company as VP Business Development (EMEA), based in Switzerland.
"We understand that it has been a challenging time as business conditions have changed during the Covid-19 crisis", said Steven Goh, incoming CEO. "We're grateful to Kenneth Ting for his contributions that positioned Achiko for future success and wish him well in his future endeavours. Going forward, we are rising to the opportunities presented by Teman Sehat and an exclusive license with Regenacellx over a novel Covid-19 testing system and look forward to being able to demonstrate progress in ensuing months".
About Achiko AG Headquartered in Switzerland, with a global market focus, Achiko AG (ISIN CH0522213468) is an entrepreneurial platform company, utilising the knowledge and experience of its people and key technologies to enable transformation in various industries.
Through innovations in technology and regulation along with the company's unique operating footprint from Europe to Asia, Achiko seeks to transform markets and bring unique value to its customers, people, and shareholders. Achiko's core platform consists of user registration and payment services which are accessible to application developers. A messaging service and other community based social features are being launched in late 2020. Achiko supports innovations in healthcare through its Teman Sehat ("Health Buddy") mobile application ecosystem, as well as consumer payments and finance and games and entertainment.
Further information about Achiko can be found at https://www.achiko.com.
Further information about the Teman Sehat ecosystem can be found at https://www.temansehat.co.
Further information about Regenacellex can be found at https://regenacellx.com.
Press Contact:Germany and Austria Axel Mühlhaus / Dr. Sönke Knop edicto GmbH E: firstname.lastname@example.org T: +49 69 90 55 05-51
Switzerland Marcus Balogh Farner Consulting Ltd. E: email@example.com T: +41 44 266 67 67
Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
End of ad hoc announcement Language: English Company: Achiko AG Lavaterstrasse 66 8002 Zurich
Switzerland Internet: https://investor.achiko.com/ ISIN: CH0522213468 Valor: 48788430 Listed: SIX Swiss Exchange EQS News ID: 1104563 End of Announcement EQS Group News Service
1104563 29-Jul-2020 CET/CEST